Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mind Medicine (MindMed) Inc
Net Income (Common)
Mind Medicine (MindMed) Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Net Income (Common)
-$168.1m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-112%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Net Income (Common)
$157m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Net Income (Common)
-CA$326.6m
|
CAGR 3-Years
53%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Net Income (Common)
-CA$15.8m
|
CAGR 3-Years
64%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Net Income (Common)
-$9.4m
|
CAGR 3-Years
62%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Net Income (Common)
-CA$5.4m
|
CAGR 3-Years
44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Mind Medicine (MindMed) Inc
Glance View
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.
See Also
What is Mind Medicine (MindMed) Inc's Net Income (Common)?
Net Income (Common)
-168.1m
USD
Based on the financial report for Sep 30, 2025, Mind Medicine (MindMed) Inc's Net Income (Common) amounts to -168.1m USD.
What is Mind Medicine (MindMed) Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-112%
Over the last year, the Net Income (Common) growth was -72%. The average annual Net Income (Common) growth rates for Mind Medicine (MindMed) Inc have been -35% over the past three years , -51% over the past five years , and -112% over the past ten years .
